This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience, to the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board. BIO is the world's largest biotechnology industry trade organization.
“As an entrepreneur in the life sciences, Dr. Dipp is committed to developing new treatments that will improve the lives of patients, and we look forward to her contributions to the BIO Board as we continue to support innovation that leads to a better quality of life,” said Cartier Esham, BIO’s Executive Vice President of Emerging Concepts.
In addition to her role as founding Chief Executive Officer of OvaScience, Dr. Dipp is also a Founder and Partner of Longwood Fund, which founds and invests in healthcare companies such as OvaScience, Alnara, Sirtris, and Verastem. Further, Dr. Dipp serves on the Beth Israel Deaconess Medical Center Board of Trustees, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board. She holds an M.D. and a Ph.D. from the University of Oxford.
“I am delighted to be joining the BIO Emerging Companies Governing Board and work alongside other industry leaders who share the same passion and perseverance to translate major discoveries into products that can improve people’s lives,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “At OvaScience, our technology platform is based on a groundbreaking discovery that enables a unique approach to developing treatments for female infertility, a disease that lacks new options for women.”
OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPC
SM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, OvaScience is developing potential next generation
in vitro fertilization (IVF) technologies. The Company currently has two product candidates in development: OvaTure
SM, which seeks to create mature fertilizable eggs from a woman’s own EggPCs without the need for hormone injections, and AUGMENT
SM, which aims to improve egg quality and increase the success of IVF. OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit
www.ovascience.com and connect with us on
Forward-Looking StatementsThis press release includes forward-looking statements about the prospects for the Company’s technology in addressing female infertility, the Company’s strategy, future plans and prospects, including statements regarding the planned discovery, development and commercialization of the Company’s product candidates. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates (AUGMENT and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products;our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events.We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.